56.26
price up icon2.01%   1.11
after-market アフターアワーズ: 56.26
loading
前日終値:
$55.15
開ける:
$55.61
24時間の取引高:
681.18K
Relative Volume:
0.80
時価総額:
$3.49B
収益:
$45.48M
当期純損益:
$169.95M
株価収益率:
21.47
EPS:
2.62
ネットキャッシュフロー:
$230.85M
1週間 パフォーマンス:
+1.88%
1か月 パフォーマンス:
+1.02%
6か月 パフォーマンス:
+48.09%
1年 パフォーマンス:
+39.67%
1日の値動き範囲:
Value
$55.20
$57.10
1週間の範囲:
Value
$53.02
$57.10
52週間の値動き範囲:
Value
$32.50
$60.60

Protagonist Therapeutics Inc Stock (PTGX) Company Profile

Name
名前
Protagonist Therapeutics Inc
Name
セクター
Healthcare (1164)
Name
電話
(510) 474-0170
Name
住所
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Name
職員
124
Name
Twitter
Name
次回の収益日
2025-05-02
Name
最新のSEC提出書
Name
PTGX's Discussions on Twitter

PTGX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
PTGX
Protagonist Therapeutics Inc
56.26 3.42B 45.48M 169.95M 230.85M 2.62
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.83 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.63 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.79 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
595.19 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.51 31.54B 3.81B -644.79M -669.77M -6.24

Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-06-17 開始されました Citigroup Buy
2024-12-06 開始されました BMO Capital Markets Outperform
2024-12-06 開始されました Goldman Neutral
2024-11-05 開始されました Wedbush Outperform
2024-09-24 開始されました TD Cowen Buy
2024-09-09 開始されました Truist Buy
2023-10-30 開始されました CapitalOne Overweight
2023-05-25 再開されました Jefferies Buy
2022-08-25 開始されました JMP Securities Mkt Outperform
2022-02-11 開始されました BTIG Research Buy
2021-10-12 アップグレード JP Morgan Neutral → Overweight
2021-10-11 アップグレード Northland Capital Market Perform → Outperform
2021-09-20 ダウングレード JP Morgan Overweight → Neutral
2021-05-24 開始されました JMP Securities Mkt Outperform
2021-05-24 開始されました Northland Capital Outperform
2021-01-06 開始されました JP Morgan Overweight
2020-12-16 開始されました Piper Sandler Overweight
2020-09-18 繰り返されました H.C. Wainwright Buy
2020-07-15 開始されました Jefferies Buy
2020-05-18 繰り返されました H.C. Wainwright Buy
2019-07-08 開始されました H.C. Wainwright Buy
2019-05-09 アップグレード Stifel Hold → Buy
2018-12-06 開始されました Nomura Buy
2018-01-29 開始されました Stifel Buy
2017-07-21 開始されました BTIG Research Buy
すべてを表示

Protagonist Therapeutics Inc (PTGX) 最新ニュース

pulisher
06:35 AM

Protagonist therapeutics CEO Patel sells $570k in stock By Investing.com - Investing.com India

06:35 AM
pulisher
06:32 AM

What is the dividend policy of Protagonist Therapeutics Inc. stockFree Stock Market Return Analysis - jammulinksnews.com

06:32 AM
pulisher
05:48 AM

What are Protagonist Therapeutics Inc. company’s key revenue driversDaily Trading Picks Backed By Experts - jammulinksnews.com

05:48 AM
pulisher
01:49 AM

What catalysts could drive Protagonist Therapeutics Inc. stock higher in 2025Capitalize on trading strategies that deliver - jammulinksnews.com

01:49 AM
pulisher
Jul 27, 2025

What institutional investors are buying Protagonist Therapeutics Inc. stockUnlock exclusive stock market forecasts - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is Protagonist Therapeutics Inc. a growth stock or a value stockGame-changing returns - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Protagonist Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayShort Squeeze Radar - metal.it

Jul 27, 2025
pulisher
Jul 26, 2025

Does Protagonist Therapeutics Inc. stock pay reliable dividendsFree Consultation - metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

Johnson & Johnson Submits NDA for Protagonist-Partnered Icotrokinra to FDA for Plaque Psoriasis - MSN

Jul 25, 2025
pulisher
Jul 24, 2025

Protagonist Therapeutics Inc. Stock Analysis and ForecastExponentially increasing returns - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

What analysts say about Protagonist Therapeutics Inc. stockHigh-performance investment picks - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Newport Daily News

Jul 24, 2025
pulisher
Jul 23, 2025

CEO’s Major Stock Sale Shakes Up Protagonist Therapeutics! - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

Protagonist Therapeutics CEO Patel sells $2.88 million in shares By Investing.com - Investing.com India

Jul 23, 2025
pulisher
Jul 23, 2025

Protagonist Therapeutics CEO Patel sells $2.88 million in shares - Investing.com

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Protagonist Therapeutics Inc. stock priceDynamic capital growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is Protagonist Therapeutics Inc. a good long term investmentBreakout stock performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - Lubbock Avalanche-Journal

Jul 22, 2025
pulisher
Jul 21, 2025

Polycythemia Vera Pipeline 2025: Latest FDA Approvals, - openPR.com

Jul 21, 2025
pulisher
Jul 21, 2025

Protagonist Announces Submission of NDA for First Icotrokinra U. - GuruFocus

Jul 21, 2025

Protagonist Therapeutics Inc (PTGX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$23.09
price down icon 1.32%
$37.06
price up icon 1.06%
$101.75
price down icon 2.12%
$27.45
price down icon 4.26%
$112.79
price down icon 2.19%
biotechnology ONC
$294.51
price up icon 1.04%
大文字化:     |  ボリューム (24 時間):